Table 2

Effects of capsazepine upon the antiproliferative effects of AEA, 2-AG, and olvanil in C6 glioma cells

CapsazepineCell Number (× 103well−1)
ControlAEA (3 μM)2-AG (3 μM)Olvanil (3 μM)
μM
 030.8  ± 0.47  [8]8.3  ± 0.422-c  [7]11.1  ± 0.512-c  [8]18.3  ± 0.282-c  [3]
 128.1  ± 0.892-a  [7]18.5  ± 0.702-b  [9]28.6  ± 0.142-b  [4]18.9  ± 0.40  [4]
 520.5  ± 0.722-b  [3]23.8  ± 1.32-b  [3]
1013.7  ± 0.462-b  [7]21.2  ± 0.832-b  [7]20.1  ± 0.322-b  [4]15.1  ± 0.33  [4]

C6 glioma cells were treated daily for 4 days with the concentrations of compounds shown, as described under Experimental Procedures. Shown are means ± S.E.M., with the number of experiments given in brackets. The data with 0 and 1 μM capsazepine are also shown in Fig. 5. Statistical significance was determined using the whole data set (i.e., including the combination of capsazepine and the SR compounds shown in Fig. 5).

  • 2-a  p < 0.05,

  • 2-b  p < 0.001 versus the corresponding values for the same AEA/2-AG/olvanil treatment in the absence of capsazepine.

  • 2-c  p < 0.001 versus the corresponding control values in the absence of capsazepine.